MAPLE-HCM

Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM

The MAPLE-HCM trial reveals that aficamten significantly outperforms metoprolol in reducing LVOT gradients and promoting favorable cardiac remodeling in patients with symptomatic obstructive HCM, signaling a potential shift in first-line th

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy